Abstracts Archive - Page 2161 of 2425 - ACR Meeting Abstracts

Abstract Number: 1347 • 2013 ACR/ARHP Annual Meeting
A Multi-Biomarker Disease Activity Score For Rheumatoid Arthritis Predicts Radiographic Damage In The BeSt Study
I.M. Markusse¹, L. Dirven¹, M. van den Broek¹, K.H. Han², M.F. van Lieshout³, N. Riyazi⁴, R.J. Bolce⁵, E.H. Sasso⁵, P.J.S.M. Kerstens⁶, W.F. Lems⁷, T.W.J. Huizinga¹ and C.F. Allaart¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ³Rheumatology, Spaarne Hospital, Hoofddorp, Netherlands, ⁴Rheumatology, Haga Hospital, The Hague, Netherlands, ⁵Crescendo Bioscience Inc., South San Francisco, CA, ⁶Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁷Rheumatology, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: To determine whether a multi-biomarker disease activity (MBDA) score could predict radiographic damage progression in patients with rheumatoid arthritis (RA). Methods: The BeSt study…
Abstract Number: 1348 • 2013 ACR/ARHP Annual Meeting
Initial Combination Therapy In Early Rheumatoid Arthritis: Which Patients Benefit?
I.M. Markusse¹, K.H. Han², A.J. Peeters³, H.K Ronday⁴, P.J.S.M. Kerstens⁵, T.W.J. Huizinga¹, W.F. Lems⁶ and C.F. Allaart¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ³Rheumatology, Reinier de Graaf Gasthuis, Delft, Netherlands, ⁴Rheumatology, Haga Hospital, The Hague, Netherlands, ⁵Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁶Rheumatology, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: Initial combination therapy has proven to be effective in early rheumatoid arthritis (RA) patients. To determine which patients benefit from initial combination therapy. Methods:…
Abstract Number: 1349 • 2013 ACR/ARHP Annual Meeting
High Rate Of Improvement In Serum Matrix Metalloproteinase-3 Levels At 4 Weeks Predict Remission At 52 Weeks In RA Patients With Adalimumab Therapy
Yosuke Hattori¹, Atsushi Kaneko¹, Daihei Kida², Hisato Ishikawa³, Toshihisa Kojima⁴ and Naoki Ishiguro⁵, ¹Orthopedic Surgery and Rheumatology, Nagoya Medical Center, Nagoya, Japan, ²Department of Rheumatology and Orthopedic Surgery, Nagoya Medical Center, Nagoya, Japan, ³Nagoya Medical Center, nagano, Japan, ⁴Orthopedic Surgery and Rheumatology, Nagoya University Hospital, Nagoya, Japan, ⁵Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
Background/Purpose : Serum MMP-3 is a specific inflammatory marker of the synovium in patients with rheumatoid arthritis (RA). Our aim in this study is to…
Abstract Number: 1350 • 2013 ACR/ARHP Annual Meeting
Factors Influencing Selection Of Biologic Therapy and Comparative Effectiveness In Patient Reported Outcomes Among Patients With Rheumatoid Arthritis
Iris Navarro-Millan¹, Lang Chen¹, Leslie R. Harrold², Lisa Herrinton³, Liyan Liu³ and Jeffrey R. Curtis⁴, ¹Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²University of Massachusetts Medical School, Worcester, MA, ³Division of Research, Kaiser Permanente, Oakland, CA, ⁴Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Treatment of rheumatoid arthritis (RA) with biologics is increasingly common. A better understanding of factors that influence the selection of RA therapies and comparative effectiveness…
Abstract Number: 1351 • 2013 ACR/ARHP Annual Meeting
A Comparison Of The Clinical Effectiveness Of Treatment Strategies For Active RA Patients : Using a Prospective Biologic Registry (BIOPSY) and an RA Specific Cohort (KORONA)
Yoon-Kyoung Sung^1,2, Soo-Kyung Cho^1,2, Chan-Bum Choi^3,4, Soyoung Won⁵, So-Young Bang⁶, Hoon-Suk Cha⁷, Jung-Yoon Choe⁸, Won Tae Chung⁹, Seung-Jae Hong¹⁰, Jae-Bum Jun⁴, Hyoun Ah Kim¹¹, Jinseok Kim¹², Seong-Kyu Kim⁸, Tae-Hwan Kim⁴, Hye-Soon Lee¹³, Jaejoon Lee⁷, Jisoo Lee¹⁴, Shin-Seok Lee¹⁵, Sung Won Lee¹⁶, Yeon-Ah Lee¹⁰, Seong-Su Nah¹⁷, Chang-Hee Suh¹⁸, Dae-Hyun Yoo⁴, Bo Young Yoon¹⁹ and Sang-Cheol Bae^1,2, ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Department of Rheumatology, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ³Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ⁴Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁵Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ⁶Hanyang University Guri Hospital, Guri, South Korea, ⁷Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁸Catholic University of Daegu School of Medicine, Daegu, South Korea, ⁹Division of Rheumatology, Department of Internal Medicine, Dong-A University Hospital, Busan, South Korea, ¹⁰Division of Rheumatology, Department of Internal Medicine, Kyung Hee University, Seoul, South Korea, ¹¹Ajou University Hospital, Suwon, South Korea, ¹²Division of Rheumatology, Internal Medicine, Jeju National University Hospital, Jeju, Korea, South Korea, ¹³Department of Rheumatology, Hanyang University Guri Hospital, Guri, South Korea, ¹⁴Internal Medicine, Ewha Womans University Mokdong Hospital, Seoul, South Korea, ¹⁵Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, South Korea, ¹⁶Rheumatology, Dong-A University Hospital, Busan, South Korea, ¹⁷Division of Rheumatology, Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Cheonan, South Korea, ¹⁸Department of Rheumatology, Ajou University Hospital, Suwon, South Korea, ¹⁹Inje University Ilsan Paik Hospital, Goyang, South Korea
Background/Purpose: The results from RCTs may not be generalizable to clinical practice because of their inclusion and exclusion criteria. Instead, observational cohorts and registries might…
Abstract Number: 1352 • 2013 ACR/ARHP Annual Meeting
What Factors Lead To Achieve and Sustain Remission In Rheumatoid Arthritis Patients With Moderate To High Disease Activity?
Soo-Kyung Cho^1,2, Yoon-Kyoung Sung^1,2, Jeeseon Shim³, Chan-Bum Choi^4,5, Jung-Yoon Choe⁶, Won Tae Chung⁷, Seung-Jae Hong⁸, Jae-Bum Jun⁵, Tae-Hwan Kim⁹, Tae-Jong Kim¹⁰, Eun-Mi Koh¹¹, Jisoo Lee¹², Shin-Seok Lee¹⁰, Sung Won Lee¹³, Dae-Hyun Yoo⁵ and Sang-Cheol Bae^1,2, ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Department of Rheumatology, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ³Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ⁴Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ⁵Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁶Catholic University of Daegu School of Medicine, Daegu, South Korea, ⁷Division of Rheumatology, Department of Internal Medicine, Dong-A University Hospital, Busan, South Korea, ⁸Division of Rheumatology, Department of Internal Medicine, Kyung Hee University, Seoul, South Korea, ⁹Division of Rheumatology, Department of Internal Medicine, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ¹⁰Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, South Korea, ¹¹Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ¹²Internal Medicine, Ewha Womans University Mokdong Hospital, Seoul, South Korea, ¹³Rheumatology, Dong-A University Hospital, Busan, South Korea
Background/Purpose: Clinical remission has now become the treatment goal in rheumatoid arthritis (RA), but it is not common in clinical practice. This study aimed to…
Abstract Number: 1353 • 2013 ACR/ARHP Annual Meeting
Remission After Twelve Month Of Treatment In The Prague Early Rheumatoid Arhritis Cohort
Herman F. Mann¹, Olga Ruzickova², Olga Sleglova¹, Marketa Fojtikova³, Dana Tegzova⁴, Sarka Forejtova² and Ladislav Senolt⁵, ¹Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Prague, Czech Republic, ²Institute of Rheumatology, Prague, Prague, Czech Republic, ³Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, ⁴Institute of Rheumatology, Prague, Czech Republic, ⁵Department of Clinical and Experimental Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Institute of Rheumatology, Prague, Czech Republic
Background/Purpose: Recent data have demonstrated that early treatment with disease modifying anti-rheumatic drugs (DMARDs) improves outcome in patients with Rheumatoid arthritis (RA). Early arthritis clinic…
Abstract Number: 1354 • 2013 ACR/ARHP Annual Meeting
Successful Self-Administration Of Methotrexate In Rheumatoid Arthritis Patients Using a Prefilled Autoinjector Pen
Jaime Pachon¹, Alan Kivitz², Kay-Uwe Heuer³ and Uwe Pichlmeier³, ¹Arthritis and Rheumatic Care Center, Miami Research Associates, South Miami, FL, ²Altoona Center for Clinical Research, Duncansville, PA, ³medac GmbH, Wedel, Germany
Background/Purpose: Methotrexate (MTX) is the most commonly used and recommended DMARD for the treatment of RA. SC administered MTX is well absorbed and appears to…
Abstract Number: 1356 • 2013 ACR/ARHP Annual Meeting
Disease Activity Of Rheumatoid Arthritis Is Influenced By Seasonal Change, As Analyzed Based On a Nationwide Japanese Cohort Database
Tetsuji Sawada¹, Hiroaki Mori², Kota Shimada³, Haeru Hayashi¹, Koichiro Tahara¹, Jinju Nishino⁴ and Shigeto Tohma⁵, ¹Rheumatology, Tokyo Medical University, Tokyo, Japan, ²Rheumatology, Tokyo Meidical University, Tokyo, Japan, ³Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan, ⁴Nishino Clinic, Orthopedics and Rheumatology, Tokyo, Japan, ⁵Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan
Background/Purpose: Previous studies have suggested that environmental factors, such as weather, humidity and seasonal change, may affect rheumatoid arthritis (RA). In the present study, we…
Abstract Number: 1330 • 2013 ACR/ARHP Annual Meeting
Prednisone Use Associated With Worse Outcomes In Rheumatoid Arthritis Pregnancies
Prateek Chaudhary¹ and M. E. B. Clowse², ¹Division of Rheumatology, Duke University Medical Center, Durham, NC, ²Rheumatology, Duke University Medical Center, Durham, NC
Background/Purpose: Prior reports suggest that disease activity in rheumatoid arthritis (RA) improves in the setting of pregnancy. However, prior studies report half of patients having…
Abstract Number: 1316 • 2013 ACR/ARHP Annual Meeting
MMP3 As a Predictor Identifying a Subgroup Of Rheumatoid Patients Who Are Successfully Treated With Methotrexate (MTX) Alone But Still Subject To Radiographic Progression
Shunichi Shiozawa¹, Yasushi Tanaka², Ryosuke Yoshihara², Miki Murata², Takashi Yamane³, Chihiro Tanaka², Noriaki Yo³ and Kazuko Shiozawa², ¹Department of Medicine, Kyushu University Beppu Hospital, Beppu, Japan, ²The Rheumatic Diseases Center, Kohnan Kakogawa Hospital, Kakogawa, Japan, ³Kohnan Kakogawa Hospital, Kakogawa, Japan
Background/Purpose: To discover the prognostic factor identifying a subgroup with clinical relevant radiographic progression (CRRP) and rapid radiographic progressoion (RRP) among rheumatoid patients successfully treated…
Abstract Number: 1317 • 2013 ACR/ARHP Annual Meeting
Methotrexate Optimization (ie introduction during the first 3 months and with dose escalation at 6 months at least at 20mg/w or 0.3mg/kg/w) Is Associated With Better Clinical Outcomes In Daily Practice: Results From The Espoir Cohort
Cécile Gaujoux-Viala¹, Simon Paternotte², Bernard Combe³, Maxime Dougados⁴ and Bruno Fautrel⁵, ¹EA 2415, Montpellier I University, Nîmes University Hospital, Rheumatology Department, Nîmes, France, ²Rheumatology Department, Paris- Descartes University, Cochin hospital, Paris, France, ³Rheumatology, Lapeyronie Hospital, Montpellier I university, Montpellier, France, ⁴Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, ⁵Paris 6 – Pierre et Marie Curie University; AP-HP, Rheumatology, Pitié-Salpêtrière Hospital, - GRC-UPMC 08 – EEMOIS, Paris, France
Background/Purpose: Methotrexate (MTX) is recommended as the first DMARD in rheumatoid arthritis (RA) at a weekly dose of 20-25mg in combination with folic acid supplementation.…
Abstract Number: 1318 • 2013 ACR/ARHP Annual Meeting
Prevalence and Impact Of Soft Tissue Manifestations In Early Inflammatory Arthritis: Results From The Canadian Early Arthritis Cohort
Mihaela Popescu¹, Edith Villeneuve², Boulos Haraoui³, Gilles Boire⁴, Carol A. Hitchon⁵, Edward C. Keystone⁶, Janet E. Pope⁷, J. Carter Thorne⁸, Diane Tin⁹ and Vivian P. Bykerk⁶, ¹Internal Medecine, University of Montreal, Montreal, QC, Canada, ²Rheumatology, Institut de Rhumatologie de Montréal, Montreal, QC, Canada, ³Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada, ⁴Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁵Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ⁶Medicine, Mount Sinai Hospital/University of Toronto, Toronto, ON, Canada, ⁷St Joseph Health Care, London, ON, Canada, ⁸Southlake Regional Health Centre, Newmarket, ON, Canada, ⁹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada
Background/Purpose: It is increasingly recognized that soft tissue inflammation in patients with inflammatory arthritis is frequent and might be of clinical importance. However, when therapeutic adjustments are made,…
Abstract Number: 1319 • 2013 ACR/ARHP Annual Meeting
Diagnostic Value Of Anti-Citrullinated Proteins Antibodies In Rheumatoid Arthritis
Claudia L. Giraldo¹, Rafael Chaparro del Moral², Mercedes Ciancio^3,4, Oscar L. Rillo⁵, Emilia Saint Martin⁶, Emilce Schneeberger⁷, Gustavo Citera⁷, Federico Zazzetti⁸, Amalia Schiel⁹ and Juan C. Barreira¹⁰, ¹Rheumatology, Hospital Gral. de Agudos Dr. E. Tornú, Buenos Aires, Argentina, ²Rheumatology Section, Hospital General de Agudos Dr. E. Tornú, Buenos Aires, Argentina, ³Hospital General de Agudos "Dr. E. Tornú", Buenos Aires, Argentina, ⁴Biochemestry, Buenos Aires, Argentina, ⁵Rheumatology, Hospital General de Agudos "Dr. E. Tornú", Buenos Aires, Argentina, ⁶Rheumatology, Instituto de Rehabilitacion Psicofisica, Buenos Aires, Argentina, ⁷Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁸Rheumatology, Buenos Aires Hospital Britanico, Buenos Aires, Argentina, ⁹Central Laboratory, British Hospital, Buenos Aires, Argentina, ¹⁰Rheumatology, Buenos Aires British Hospital, Buenos Aires, Argentina
Background/Purpose: Citrulline and vimentin are some of the proteins used as antigens for anti-citrullinated proteins antibodies (ACPAs) detection for the diagnosis of rheumatoid arthritis (RA).…
Abstract Number: 1320 • 2013 ACR/ARHP Annual Meeting
Categorization Of Rheumatoid Arthritis Subjects By Rheumatoid Factor and Anti-Cyclic Citrullinated Autoantibody Status Identifies Rheumatoid Arthritis Subjects With Different Characteristics
Swati Modi¹, Mariely Nieves-Plaza², Donald M. Jones³, Erich R Wilkerson⁴, Christine L. Amity⁵, Kelly A. Reckley⁶, Ilinca D. Metes⁷, Jason Lyons⁸, Heather Eng⁹, Stephen R. Wisniewski⁹ and Marc C. Levesque¹⁰, ¹Rheumatology, University of Pittsburgh, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA, ³Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁴Medicine, University of Pittsburgh, Pittsburgh, PA, ⁵Rheumatology & Clinical Immun, Univ of Pittsburgh, Pittsburgh, PA, ⁶Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁷Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁸School of Public Health, Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA, ⁹Epidemiology Data Center, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, ¹⁰Division of Rheumatology and Clinical Immunology, University of Pittsburgh Department of Medicine, Pittsburgh, PA
Background/Purpose: Rheumatoid factor (RF) and anti-citrullinated cyclic peptide (CCP) antibodies have been used to diagnose rheumatoid arthritis (RA) patients, although there is substantial heterogeneity among…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].